van Burik J A, Hackman R C, Nadeem S Q, Hiemenz J W, White M H, Flowers M E, Bowden R A
Department of Medicine, University of Washington, Seattle, USA.
Clin Infect Dis. 1997 Jun;24(6):1154-60. doi: 10.1086/513654.
To evaluate the spectrum of nocardiosis after marrow transplantation, we reviewed the medical records of 27 patients with nocardiosis who were treated at three centers, and we reviewed the findings of three cases reported in the literature. Nocardial involvement was defined as invasive nocardiosis (n = 25), colonization (n = 4), or contamination (n = 1). The median time to the diagnosis of nocardiosis after marrow transplantation was 210 days. Nocardia asteroides complex accounted for 96% of isolates. All 25 invasive infections occurred in allogeneic marrow recipients. Ten (40%) of 25 patients with invasive nocardiosis were receiving double-strength oral trimethoprimsulfamethoxazole twice weekly as prophylaxis for Pneumocystis carinii pneumonia. Treatment regimens for nocardiosis included sulfonamides; synergistic agents were also often added. The overall survival rate at 6 years was 34%; survival from the infection itself was 84%. Two of four nocardiosis-related deaths also involved other pathogens. The incidence of nocardiosis among allogeneic marrow recipients averaged 0.3% over 25 years. We conclude that nocardiosis is a rare infection that occurs later after marrow transplantation than other infections and that is marginally associated with increased mortality among long-term survivors of allogeneic marrow transplantation.
为评估骨髓移植后诺卡菌病的范围,我们回顾了在三个中心接受治疗的27例诺卡菌病患者的病历,并查阅了文献中报道的3例病例的研究结果。诺卡菌感染定义为侵袭性诺卡菌病(n = 25)、定植(n = 4)或污染(n = 1)。骨髓移植后诊断诺卡菌病的中位时间为210天。星形诺卡菌复合体占分离菌株的96%。所有25例侵袭性感染均发生在异基因骨髓移植受者中。25例侵袭性诺卡菌病患者中有10例(40%)正在接受双倍剂量的口服甲氧苄啶磺胺甲恶唑,每周两次,作为卡氏肺孢子虫肺炎的预防用药。诺卡菌病的治疗方案包括磺胺类药物;通常还会添加协同剂。6年时的总生存率为34%;感染本身的生存率为84%。4例与诺卡菌病相关的死亡中有2例还涉及其他病原体。在25年期间,异基因骨髓移植受者中诺卡菌病的发病率平均为0.3%。我们得出结论,诺卡菌病是一种罕见的感染,发生在骨髓移植后比其他感染更晚,并且与异基因骨髓移植长期存活者的死亡率略有增加有关。